14194-05-9

Upstream product

• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 
• 101-97-3 Ethyl 2-phenylethanoate 
• 75-36-5 acetyl chloride 
• 201230-82-2 carbon monoxide 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 105-36-2 ethyl bromoacetate 
• 214360-49-3 1-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethanone 

Downstream Products

• 2084-13-1 3-carboxymethyl-benzoic acid 
• 63476-44-8 [3-(3-Oxo-cyclohex-1-enyl)-phenyl]-acetic acid 
• 18749-47-8 3-carboxymethylacetophenone 
• 19806-17-8 1,3-benzenediacetic acid 

Relevant academic research and scientific papers

OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs)

A group of 4-(4-methanesulfonylphenyl)-3-phenyl-2(5H)furanones possessing an acetyl, 3-oxobut-1-ynyl, [hydroxyl(or alkoxy)imino]alkyl, [hydroxyl(or alkoxy)imino]alkynyl, and N-alkoxy(or N-phenoxy)carbonyl-N-hydroxy-N-ethylamino substituents at the para-position of the C-3 phenyl ring of rofecoxib were synthesized. This group of compounds was designed for evaluation as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs) that exhibit in vivo anti-inflammatory and analgesic activities. In vitro COX-1/COX-2, and 5-LOX/15-LOX, isozyme inhibition structure-activity relationships identified 3-[4-(1-hydroxyimino)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (17a) having an optimal combination of COX-2 (COX-2 IC50 = 1.4 μM; COX-2 SI > 71), and 5-LOX and 15 LOX (5-LOX IC50 = 0.28 μM; 15-LOX IC50 = 0.32 μM), inhibitory effects. It was also discovered that 3-[4-(3-hydroxyiminobut-1-ynyl)phenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (18a) possesses dual COX-2 (IC50 = 2.7 μM) and 5-LOX (IC50 = 0.30 μM) inhibitor actions. Further in vivo studies employing a rat carrageenan-induced paw edema model showed that the oxime compounds (17a, 18a) were more potent anti-inflammatory agents than the 5-LOX inhibitor caffeic acid, and 15-LOX inhibitor nordihydroguaiaretic acid (NDGA), but less potent than the selective COX-2 inhibitor celecoxib. The results of this investigation showed that incorporation of a para-oxime moiety on the C-3 phenyl ring of rofecoxib provides a suitable template for the design of dual inhibitors of the COX and LOX enzymes.

Regioselective acylation of (5-alkylidene-1,3-cyclohexadiene)tricarbonyliron complexes by the reaction with organometallic reagents

Reaction of [(1,2,3,4-η)-5-alkylidene-1,3-cyclohexadiene]-tricarbonylirons and organometallic reagents generates acyl-[(1,2,3,4,5-η)-1-alkylcydohexadienyl]dicarbonylirons. The acyl group in these complexes migrates to the cyclohexadienyl moiety under carb